These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22421924)

  • 21. S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors.
    Huang P; Meng L; Tan J; Gu X; Huang M; Huang F; Ma R; Wang J
    Life Sci; 2021 Apr; 270():119136. PubMed ID: 33508289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
    Maida A; Lovshin JA; Baggio LL; Drucker DJ
    Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.
    McGlone ER; Hope DCD; Davies I; Dore M; Goldin R; Jones B; Liu Z; Li JV; Vorkas PA; Khoo B; Carling D; Minnion J; Bloom SR; Tan TM
    Biomed Pharmacother; 2024 Jul; 176():116888. PubMed ID: 38861859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
    Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
    Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor.
    Sowden GL; Drucker DJ; Weinshenker D; Swoap SJ
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R962-70. PubMed ID: 17038440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats.
    Price SL; Minnion JS; Bloom SR
    Curr Ther Res Clin Exp; 2015 Dec; 77():111-5. PubMed ID: 26843896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
    Shankar SS; Shankar RR; Mixson LA; Miller DL; Pramanik B; O'Dowd AK; Williams DM; Frederick CB; Beals CR; Stoch SA; Steinberg HO; Kelley DE
    Diabetes; 2018 Jun; 67(6):1105-1112. PubMed ID: 29545266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice.
    Ma T; Huo S; Xu B; Li F; Wang P; Liu Y; Lei H
    Eur J Med Chem; 2020 Oct; 203():112496. PubMed ID: 32682196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21.
    Kim T; Nason S; Holleman C; Pepin M; Wilson L; Berryhill TF; Wende AR; Steele C; Young ME; Barnes S; Drucker DJ; Finan B; DiMarchi R; Perez-Tilve D; Tschöp M; Habegger KM
    Diabetes; 2018 Sep; 67(9):1773-1782. PubMed ID: 29925501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity.
    Zhihong Y; Chen W; Qianqian Z; Lidan S; Qiang Z; Jing H; Wenxi W; Bhawal R
    Peptides; 2023 Apr; 162():170955. PubMed ID: 36669563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxyntomodulin analogue increases energy expenditure via the glucagon receptor.
    Scott R; Minnion J; Tan T; Bloom SR
    Peptides; 2018 Jun; 104():70-77. PubMed ID: 29680267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs.
    Druce MR; Minnion JS; Field BC; Patel SR; Shillito JC; Tilby M; Beale KE; Murphy KG; Ghatei MA; Bloom SR
    Endocrinology; 2009 Apr; 150(4):1712-22. PubMed ID: 19074579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling.
    Lockie SH; Heppner KM; Chaudhary N; Chabenne JR; Morgan DA; Veyrat-Durebex C; Ananthakrishnan G; Rohner-Jeanrenaud F; Drucker DJ; DiMarchi R; Rahmouni K; Oldfield BJ; Tschöp MH; Perez-Tilve D
    Diabetes; 2012 Nov; 61(11):2753-62. PubMed ID: 22933116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxyntomodulin reduces expression of glucagon-like peptide 1 receptor in the brainstem of chickens.
    Moghaddam AG; Yaghoobi MM; Jonaidi H; Mahani MT; Sepehri H
    J Anim Physiol Anim Nutr (Berl); 2010 Aug; 94(4):422-8. PubMed ID: 19663977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic Glucagon Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents.
    Kim T; Holleman CL; Nason S; Arble DM; Ottaway N; Chabenne J; Loyd C; Kim JA; Sandoval D; Drucker DJ; DiMarchi R; Perez-Tilve D; Habegger KM
    Diabetes; 2018 Nov; 67(11):2157-2166. PubMed ID: 30150304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
    Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
    Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amino acids are sensitive glucagon receptor-specific biomarkers for glucagon-like peptide-1 receptor/glucagon receptor dual agonists.
    Li W; Kirchner T; Ho G; Bonilla F; D'Aquino K; Littrell J; Zhang R; Jian W; Qiu X; Zheng S; Gao B; Wong P; Leonard JN; Camacho RC
    Diabetes Obes Metab; 2020 Dec; 22(12):2437-2450. PubMed ID: 33463043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions.
    Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2010 Dec; 80(11):1727-35. PubMed ID: 20735990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.